Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125682702 | 12568270 | 2 | F | 20160516 | 20160718 | 20160718 | 20160727 | PER | US-ELI_LILLY_AND_COMPANY-US201606010238 | ELI LILLY AND CO | 57.00 | YR | F | Y | 0.00000 | 20160727 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125682702 | 12568270 | 1 | PS | ADCIRCA | TADALAFIL | 1 | Unknown | 40 MG, QD | U | U | 21368 | 40 | MG | QD | |||||
| 125682702 | 12568270 | 2 | SS | AMBRISENTAN | AMBRISENTAN | 1 | Unknown | 10 MG, QD | 0 | 10 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125682702 | 12568270 | 1 | Pulmonary hypertension |
| 125682702 | 12568270 | 2 | Pulmonary arterial hypertension |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125682702 | 12568270 | Nasal congestion | |
| 125682702 | 12568270 | Oedema peripheral |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125682702 | 12568270 | 1 | 20160407 | 0 | ||
| 125682702 | 12568270 | 2 | 20160310 | 0 |